Why CAR T therapy works for some patients but fails for others may be getting clearer

Chimeric antigen receptor (CAR) T-cell therapy is one of oncology’s most powerful ideas: Harvest a cancer patient’s own immune cells, genetically engineer them to recognize tumor cells, multiply them in a laboratory and reinject them as a living drug. For some patients, the treatment produces extraordinary, durable remissions. For many others, however, it produces nothing, but new research sheds light on the reason.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup